Reading this on a mobile device? Try our optimized mobile version here:

February 27, 2013
Sign upForwardArchiveAdvertise
Research transforming the study of diabetes and obesity

  Top Story 
  • Circadian rhythm affects insulin activity, study shows
    The body's circadian rhythm affects insulin activity and disrupting the rhythm may raise the risk of obesity, heart disease and diabetes, according to a study in Current Biology. Vanderbilt University researchers said the study shows that when a person eats is important to health, as well as what and how much is eaten. RedOrbit (2/22) LinkedInFacebookTwitterEmail this Story
  Science & Research 
  • Study links heart attack mortality risk to enzyme in diabetic mice
    A study in the Journal of Clinical Investigation showed that pacemaker cells in the hearts of diabetic mice had higher levels of the oxidized CaMKII enzyme and sustained more cell death than pacemaker cells in non-diabetic mice, and had even higher levels of oxidation and cell death after a heart attack, increasing the risk of death after a heart attack. RedOrbit (2/16) LinkedInFacebookTwitterEmail this Story
  • First-born children face higher risk for hypertension, diabetes
    New Zealand researchers looked at 85 4- to 11-year-olds and found that first-borns had a 21% decline in insulin sensitivity and a 4 mmHg increase in blood pressure compared with other children. They also found that the eldest children tended to be taller and thinner than other children. The findings will be published in the Journal of Clinical Endocrinology & Metabolism. HealthDay News (2/12) LinkedInFacebookTwitterEmail this Story
  • Repurposed asthma drug reverses diabetes in mouse study
    Amlexanox, an off-patent asthma drug, reversed obesity, diabetes and fatty liver disease in mice, according to a study published in Nature Medicine. The drug appears to inhibit the IKK(epsilon) and TBK1 genes, which might allow the metabolic system to burn more energy, University of Michigan Life Sciences Institute researcher Alan Saltiel said. Researchers plan to test the drug in clinical trials and are working on optimized formulas. Genetic Engineering & Biotechnology News (2/11) LinkedInFacebookTwitterEmail this Story
  • Diabetes drug for adults may help obese youths lose weight
    Severely obese youths who received exenatide injections twice a day for three months lost about 7 pounds more than the placebo group, according to a study in JAMA Pediatrics. Initially approved by the FDA for adults with type 2 diabetes, exenatide showed potential "in terms of weight reduction and cardiovascular risk control," lead author Aaron Kelly said. Reuters (2/4) LinkedInFacebookTwitterEmail this Story
  • Research explores age, mortality and obesity
    Although previous research has suggested the connection between obesity and mortality becomes less important with age, researchers at Columbia University found the link between obesity and death risk grows stronger as age increases. The findings appear in the American Journal of Epidemiology. Healio/Endocrine Today (2/19) LinkedInFacebookTwitterEmail this Story
  • Other News
  Products & Innovation 
  Trends & Technology 
  • Sequester could cut access to medicines, cost 20K jobs
    FDA operations will be limited by budget sequestration if lawmakers don't move to stop an 8.2% automatic cut before March 1, the consulting firm Avalere Health warned. "An underfunded FDA could lead to FDA review clocks being reset or delayed, which would affect a sponsor’s ability to obtain product approval -- thus delaying patient access to cutting edge medical innovations," Avalere's report said. Cutting the NIH's budget could cost the nation 20,500 life science jobs and $3 billion in economic activity, advocacy group United for Medical Research said. The Hill/Healthwatch blog (2/5) , The Hill/Healthwatch blog (2/6) LinkedInFacebookTwitterEmail this Story
  • Lack of awareness impedes clinical trial enrollment
    Research institutions need to do a better job of publicizing clinical trials to recruit more adults and children, researchers say. Only 11% of U.S. adults and 5% of children have ever participated in a clinical trial, while only 64% of adults are aware of opportunities to participate and 12% of parents know about clinical trials for their children, a survey of 2,150 households found. Study results are published in the journal Clinical and Translational Science. HealthDay News (2/4) LinkedInFacebookTwitterEmail this Story
  TRI News 
  • TRI's Dr. Steven R. Smith discusses innovative calorimeter lab
    TRI's state-of-the-art calorimeter lab was recently profiled by The Orlando Sentinel, highlighting the research being conducted to help understand how people's metabolism varies. Steven R. Smith, M.D., TRI's scientific director, said the ultimate aim of this research is to develop personalized therapies for obesity and associated diseases based on an individual's metabolism, and that finding out how to turn on the fat-burning mechanism in those who are obese is "the Holy Grail." Read more here. LinkedInFacebookTwitterEmail this Story
  • Poll: There are approximately 25 metabolic disorders that can mask as typical T2D but often go misdiagnosed and undetected. Considering tomorrow is International Rare Disease Day, what is the most important way to spur therapeutic advancements for these rare metabolic disorders?
Increase funding to advance understanding of genetic underpinnings of T2D and related metabolic disorders
Enhance collaboration between the academic community and industry
Create databases to capture genetic information for T2D patients to detect patient sub-populations
Promote early detection by raising awareness of signs and symptoms of known disorders such as LADA

  • As we embark on a new year that looks to be promising for developing treatments for metabolic diseases, what was the most interesting development in scientific research in the metabolic disease space in 2012?
    The gut microbiome and obesity  26.32%
    Links between inflammation and diabetes and obesity  21.05%
    The emergence of brown fat as a therapeutic strategy for obesity and diabetes  21.05%
    Epigenetics and nutritional/maternal-fetal programming  15.79%
    Metabolomics were seen as starting to pay off  15.79%
Learn more about TRI ->News & Events  |  Research Studies  |  Contact Us

You can do anything in this world if you are prepared to take the consequences."
--W. Somerset Maugham,
British writer

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

 Recent TRI SmartBrief Issues:   Lead Editor:   Kathryn Doherty
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information